- In January 2023, Merck KGaA received approval for its KEYTRUDA (pembrolizumab) as a platinum-based chemotherapy drug by the U.S. FDA to treat stage IB, II, and IIIA non-small cell lung cancer (NSCLC). Through this approval, the company gained a competitive advantage in the cytotoxic drugs market
- In January 2022, Gilead Sciences, Inc., collaborated with Merck KGaA for clinical trials to evaluate the combination of Trodelvy, a Trop-2 targeting antibody-drug conjugate, with KEYTRUDA, an anti-PD-1 therapy for the treatment of metastatic non-small cell lung cancer (NSCLC). This collaboration offered developmental capabilities to both firms in the significant market
